| Code | CSB-RA868278MB5HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to Picankibart, targeting interleukin-23 subunit alpha (IL23A), also known as p19. IL23A combines with IL12B to form the heterodimeric cytokine IL-23, which plays a critical role in inflammatory responses by promoting the differentiation and survival of Th17 cells. IL-23 signaling drives the production of pro-inflammatory cytokines including IL-17, contributing to chronic inflammation and autoimmune pathology. Dysregulated IL-23 activity is implicated in several immune-mediated conditions, including psoriasis, psoriatic arthritis, Crohn's disease, and ankylosing spondylitis.
Picankibart is a therapeutic monoclonal antibody that selectively binds to the p19 subunit of IL-23, preventing its interaction with the IL-23 receptor and thereby inhibiting downstream inflammatory cascades. This biosimilar antibody provides researchers with a valuable tool for investigating IL-23-mediated signaling pathways, studying cytokine networks in autoimmune disease models, and exploring therapeutic mechanisms of IL-23 blockade. It supports studies in immunology, inflammation research, and the development of targeted biologics for immune-mediated disorders.
There are currently no reviews for this product.